Raymond James starts Climb Bio, Inc. (CLYM) at Strong Buy March 2026

NodeGuardian · 2026-03-12T10:11:34+00:00

Raymond James has begun coverage of Climb Bio, Inc. (CLYM) with a "Strong Buy" rating, indicating confidence in its pipeline and market position. Meyka AI also rates CLYM a "B," reflecting its financial and performance metrics.

NodeGuardian

2026-03-12 10:11:34

Abstract generation in progress

Raymond James has initiated coverage of Climb Bio, Inc. (CLYM) with a “Strong Buy” rating as of March 10, 2026, marking the first major analyst coverage for the company. While no public price target was provided, the rating signals confidence in Climb Bio’s pipeline potential and market positioning. Meyka AI also rates CLYM with a “B” grade, considering various financial and market performance metrics.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.